Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

MS drug helps reduce vision loss

17.04.2007
A drug that slows disability and reduces relapse rates in multiple sclerosis (MS) has been found to also reduce vision loss in patients with relapsing MS. Vision loss is one of the most common and debilitating symptoms of MS. The findings are published in the April 17, 2007, issue of Neurology®, the scientific journal of the American Academy of Neurology.

The analyses were performed on data from the AFFIRM and SENTINEL studies, which involved 2,138 men and women with relapsing multiple sclerosis from clinics in Europe, North American, Australia, and New Zealand. More than half of the people received the drug natalizumab every four weeks for two years. The rest of the group received placebo. Researchers used eye charts of low contrast letters to test the vision of the participants every 12 weeks.

The study found vision loss, defined as a worsening in score by two rows of letters on the eye chart, was reduced by as much as 47 percent among people taking natalizumab compared to those taking placebo.

"Not only does natalizumab prevent the worsening of vision loss in people with relapsing MS, we also found the drug was associated with significant reductions in the likelihood of sustained vision loss," said study author Laura J. Balcer, MD, MSCE, with the University of Pennsylvania School of Medicine in Philadelphia, PA, and member of the American Academy of Neurology. "Specifically, this drug may have implications for preventing further sustained vision loss due to inflammatory demyelination of nerve fibers that connect to the eye, which is common in MS."

However, Balcer said the potential benefits of natalizumab treatment must be weighed with the drug's potential risks or complications, including the rare, often lethal brain disease progressive multifocal leukoencephalopathy (PML), of which three confirmed cases have been reported.

In addition, data from AFFIRM and SENTINEL studies showed that low-contrast letter acuity eye chart testing is effective for assessing visual outcomes in future MS clinical trials, which have not typically included visual testing components despite vision loss being a main disability of MS.

Angela Babb | EurekAlert!
Further information:
http://www.aan.com

More articles from Health and Medicine:

nachricht Microgel powder fights infection and helps wounds heal
14.11.2018 | Michigan Technological University

nachricht Spread of deadly eye cancer halted in cells and animals
13.11.2018 | Johns Hopkins Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

Im Focus: Penn engineers develop ultrathin, ultralight 'nanocardboard'

When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure

Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...

Im Focus: Coping with errors in the quantum age

Physicists at ETH Zurich demonstrate how errors that occur during the manipulation of quantum system can be monitored and corrected on the fly

The field of quantum computation has seen tremendous progress in recent years. Bit by bit, quantum devices start to challenge conventional computers, at least...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

European Space Talks: Weltraumschrott – eine Gefahr für die Gesellschaft?

23.10.2018 | Event News

 
Latest News

Epoxy compound gets a graphene bump

14.11.2018 | Materials Sciences

Microgel powder fights infection and helps wounds heal

14.11.2018 | Health and Medicine

How algae and carbon fibers could sustainably reduce the athmospheric carbon dioxide concentration

14.11.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>